Supplemental Digital Content 5
eTable 5. Quality assessment for weight-based dosing regimens using GRADE methodology
Number of
Studies Study design Limitations Inconsistency Indirectness Imprecision Other considerations
Quality of Evidence VTE Incidence
5 Observational Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision None LOW ◯◯
⨁⨁
anti-Xa Concentration
6 Observational,
RCT Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision Not Serious2 LOW ◯◯
⨁⨁
Bleeding Complications
5 Observational Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision None LOW ◯◯
⨁⨁
1. Serious limitations include small sample size, single-center studies, loss to follow up. Additionally, Bickford et al.
(2013) was a one-arm prospective cohort which lacked a comparator group.
2. Most studies draw anti-Xa levels after the third dose of VTE chemoprophylaxis has been administered. Ludwig (2011) took measurements after the second and third doses. However, all included studies did use the same target range of 0.2-0.6 IU/mL.
Supplemental Digital Content 6
eTable 6. Quality assessment for weight-stratified dosing regimens using GRADE methodology
Number of
Studies Study design Limitations Inconsistency Indirectness Imprecision Other
considerations Quality of Evidence VTE Incidence
4 Observational Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision None LOW
◯◯
⨁⨁
anti-Xa Concentration
3 Observational Serious1 No serious
inconsistency
No serious indirectness
No serious
imprecision None LOW
◯◯
⨁⨁
Bleeding Complications
4 Observational Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision None LOW
◯◯
⨁⨁
1. Small sample size.
Supplemental Digital Content 7
eTable 7. Quality assessment for BMI-stratified dosing regimens using GRADE methodology
Number of
Studies Study design Limitations Inconsistency Indirectness Imprecision Other
considerations Quality of Evidence VTE Incidence
4 Observational;
Nonrandomized trial Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision None LOW
◯◯
⨁⨁
anti-Xa Concentration
3 Observational;
Nonrandomized trial Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision None LOW
◯◯
⨁⨁
Bleeding Complications 4
Observational;
Nonrandomized trial Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision None LOW
◯◯
⨁⨁
1. Small sample size; Mushtaq (2015) had only 4 patients in their pilot pediatric study.
Supplemental Digital Content 8
eTable 8. Quality assessment for continuous infusion dosing regimens using GRADE methodology
Number of
Studies Study design Limitations Inconsistency Indirectness Imprecision Other
considerations Quality of Evidence VTE Incidence
2 Observational Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision None VERY LOW
◯◯◯
⨁
anti-Xa Concentration
2 Observational Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision None VERY LOW
◯◯◯
⨁
Bleeding Complications
2 Observational Serious1 No serious
inconsistency
No serious indirectness
No serious
imprecision None VERY LOW
◯◯◯
⨁
1. Both studies lacked comparator groups. Shepherd et al. (2004) had a sample size of only 19 patients.
Supplemental Digital Content 9
eTable 9. Quality assessment for fixed-dose regimens using GRADE methodology
Number of Studies Study design Limitations Inconsistency Indirectness Imprecision Other
considerations Quality of Evidence VTE Incidence
26 Observational,
RCTs Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision None LOW
◯◯
⨁⨁
anti-Xa Concentration
10 Observational,
RCTs Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision None LOW
◯◯
⨁⨁
Bleeding Complications
23 Observational,
RCTs Serious1 No serious
inconsistency No serious
indirectness No serious
imprecision None LOW
◯◯
⨁⨁
1. Small sample size; loss to follow up.